Abstract:Study objective: To compare the effects of paroxetine on the pharmacokinetics and pharmacodynamics of the immediate-release (IR) and extended-release (ER) formulations of metoprolol. Design: Prospective, randomized, open-label, 3-way crossover study. Setting: General clinical research center. Subjects: Fifteen healthy volunteers with at least one active cytochrome P450 (CYP) CYP2D6 allele (CYP2D6*1 or CYP2D6*2). Intervention: In each of three phases conducted in random sequence, subjects received one of three metoprolol formulations administered on day 1: a single dose of metoprolol ER 100 mg, a single dose of metoprolol ER 200 mg, or two 100-mg doses of metoprolol IR administered 12 hours apart. Oral paroxetine 20 mg/day was then given alone on days 2-7 and coadministered with the same metoprolol formulation on day 8. Subjects received each of the other two formulations during the next two phases, with a 14-day washout period between each phase. Measurements and main results: After receiving metoprolol on days 1 (before paroxetine) and 8 (after paroxetine), S- and R-metoprolol pharmacokinetic parameters and exercise heart rate and blood pressure responses were measured. The mean area under the plasma concentration-time curve values of both S- and R-metoprolol for each formulation were increased approximately 3- and 4-fold, respectively, by paroxetine. Paroxetine significantly increased the S- and R-metoprolol maximum concentration (C(max)) of each formulation and increased the elimination half-life of both isomers approximately 2-fold. When metoprolol IR was given with paroxetine, the S-metoprolol C(max) was significantly greater than that of either the 100-mg or 200-mg ER products. The maximum effect of metoprolol IR on heart rate was significantly greater than that of metoprolol ER 200 mg, independent of whether the agents were administered alone or with paroxetine. Both the heart rate and systolic blood pressure area under the effect-time curve values were significantly decreased by paroxetine. Conclusion: Paroxetine significantly inhibits the metabolism of both metoprolol IR and ER, resulting in an increase in the magnitude and duration of [H9252]-blockade. The potential risk of adverse effects from excessive β-blockade may be greater with metoprolol IR than with metoprolol ER because of the significantly higher peak S-metoprolol plasma concentrations achieved with the IR formulation. Thus, if paroxetine treatment is indicated in patients receiving metoprolol, use of the ER formulation may reduce the risk of adverse effects.

Co-Administration Of Paroxetine Increased The Systemic Exposure Of Pravastatin In Diabetic Rats Due To The Decrease In Liver Distribution

Combined effects of atorvastatin and soybean isoflavones on hypercholesterolemia and lipoprotein metabolism

Effects of Pravastatin on Cardiac Function and Plasma Level of Brain Natriuretic Peptide in Patients with Chronic Heart Failure

Analysis of prescriptions of three selective serotonin reuptake inhibitors from a perspective of metabolic interactions

Efficacy of Statin Monotherapy or in Combination with Coenzyme A Capsule in Patients with Metabolic Syndrome and Mixed Dyslipidemia

Study on Intestinal Absorption and Liver Distribution of Pravastatin in Rats

Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol

Effect of Paroxetine Combined with Probiotics in Patients with Type 2 Diabetes Mellitus Complicated with Gastrointestinal Dysfunction and Liver Cancer

Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver

Effects of Rabeprazole on Pharmacokinetics of Clopidogrel in Rats

Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients

Clinical review of paroxetine in type 2 diabetes mellitus patients with anxiety and depression

Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats

Meta-analysis of the Efficacy and Safety of Simvastatin vs. Pravastatin in the Treatment of Hyperlipidemia

The Effect of Pravastatin on Kidney Function and Urinary Protein of Chronic Kidney Disease

Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studies

Demonstration of an Add-on Effect of Probucol and Cilostazol on the Statin-Induced Anti-Atherogenic Effects.

Study on the Effect of Fenofibrate to Pharmacokinetics of Simvastatin in Healthy Volunteers

A Control Study of Paroxetine Combined with Aripiprazoie in the Treatment of Depression.

The Effect of Pitavastatin on Blood Glucose and Its Efficacy in Diabetic Patients with Hypercholesterolemia

The Dose-Effect Relationship of Pravastatin to Vascular Endothelial Function of CHD Patients